EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antisense RNA therapies for muscular dystrophies

Virginia Arechavala-Gomeza iD, Andrea López-Martínez iD, Annemieke Aartsma-Rus iD

Journal of Neuromuscular Diseases · 2026-03 · 13 (2) · 156-166

DOI: 10.1177/22143602251324858 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 27.03.2025. Verfasst von Virginia Arechavala-Gomeza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nucleic Acid Therapeutics for Rare Diseases (NAT-RD), Biobizkaia Health Research Institute, Barakaldo, Spain. Hauptthemen laut MEDLINE: Muscular Dystrophies, RNA, Antisense, Genetic Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inherited muscular dystrophies are a heterogeneous group of diseases, caused by different types of genetic mutations. RNA therapies, and particularly antisense oligonucleotides, offer a palette of therapeutic strategies to either reduce the production of harmful proteins or to restore or increase protein expression. Consequently, they offer therapeutic promise for multiple forms of muscular dystrophies. This review outlines the different RNA therapy types considered for the treatment of Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy, emphasizing the strategies used to deliver these therapies to skeletal muscle with a focus on approaches that have reached the clinical trial stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular DystrophiesRNA, AntisenseGenetic TherapyHumansMuscular Dystrophy, DuchenneMyotonic DystrophyOligonucleotides, AntisenseMuscular Dystrophy, FacioscapulohumeralAnimals

Stichwörter der Autor:innen

antisense oligonucleotidemuscle deliverymuscular dystrophysiRNA

Substanzen

RNA, AntisenseOligonucleotides, Antisense

Autor:innen und Institutionen

  • Nucleic Acid Therapeutics for Rare Diseases (NAT-RD), Biobizkaia Health Research Institute, Barakaldo, Spain.
  • Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Virginia Arechavala-Gomeza, Andrea López-Martínez, Annemieke Aartsma-Rus

Zitieren

APA

Arechavala-Gomeza, V., López-Martínez, A., & Aartsma-Rus, A. (2026). Antisense RNA therapies for muscular dystrophies. Journal of Neuromuscular Diseases, 13(2), 156-166. https://doi.org/10.1177/22143602251324858

Vancouver

Arechavala-Gomeza V, López-Martínez A, Aartsma-Rus A. Antisense RNA therapies for muscular dystrophies. Journal of Neuromuscular Diseases. 2026;13(2):156-166. doi:10.1177/22143602251324858

BibTeX
@article{ArechavalaGomeza2026,
  author = {Arechavala-Gomeza, Virginia and López-Martínez, Andrea and Aartsma-Rus, Annemieke},
  title = {Antisense RNA therapies for muscular dystrophies},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {2},
  pages = {156--166},
  doi = {10.1177/22143602251324858}
}
Kostenlos starten →